Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved […]